Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. Melchardt · SciRah

Researcher profile · Semantic Scholar

T. Melchardt

Share profile

T. Melchardt — researcher profile on SciRah

h-index: 30
Works: 171
Citations: 2,409

Most-cited papers

Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
T. Magnes, S. Wagner, Dominik Kiem, L. Weiss +3 more
2021International Journal of Molecular Sciences65 citations Open access
Semantic Scholar
How I treat diffuse large B-cell lymphoma
T. Melchardt, A. Egle, R. Greil
2023ESMO Open63 citations Open access
Semantic Scholar
Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence
F. Huemer, M. Leisch, R. Geisberger, T. Melchardt +3 more
2020International Journal of Molecular Sciences51 citations Open access
Semantic Scholar
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
L. Pleyer, M. Leisch, A. Kourakli, E. Padron +37 more
2021The Lancet Haematology46 citations
Semantic Scholar
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
Evgenii Shumilov, J. Scholz, Maximilian Seib, P. Mazzeo +33 more
2025Blood Advances35 citations Open access
Semantic Scholar
Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study
Evgenii Shumilov, R. Wurm-Kuczera, Andrea Kerkhoff, Meng Wang +36 more
2024Blood Advances33 citations Open access
Semantic Scholar
Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.
T. Melchardt, T. Magnes, C. Hufnagl, A. Thorner +13 more
2018European Journal of Cancer31 citations
Semantic Scholar
Update on squamous cell carcinoma of the head and neck
T. Magnes, A. Egle, R. Greil, T. Melchardt
2017memo - Magazine of European Medical Oncology31 citations Open access
Semantic Scholar
Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial
T. Westphal, G. Rinnerthaler, S. Gampenrieder, J. Niebauer +10 more
2018Cancer Medicine30 citations Open access
Semantic Scholar
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
F. Huemer, T. Melchardt, Bettina Jansko, A. Wahida +10 more
2019European Journal of Haematology27 citations Open access
Semantic Scholar
Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
F. Huemer, V. Schlintl, S. Hecht, H. Hackl +4 more
2019Clinical colorectal cancer26 citations Open access
Semantic Scholar
DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma
A. Starzer, G. Heller, E. Tomasich, T. Melchardt +10 more
2022Journal for ImmunoTherapy of Cancer23 citations Open access
Semantic Scholar
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.
C. Touzeau, Roberto Mina, H. Quach, V. Hungria +44 more
2026New England Journal of Medicine21 citations
Semantic Scholar
Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
H. Ludwig, W. Poenisch, S. Knop, A. Egle +13 more
2019British Journal of Cancer21 citations Open access
Semantic Scholar
Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group
Bettina Jansko-Gadermeir, M. Leisch, F. Gassner, N. Zaborsky +9 more
2023Cancers19 citations Open access
Semantic Scholar
Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
F. Keil, Maximilian Hartl, G. Altorjai, A. Berghold +10 more
2021European Journal of Cancer19 citations
Semantic Scholar
C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling Overall Survival Prediction in Pancreatic Cancer Patients
K. Schlick, T. Magnes, F. Huemer, Lukas Ratzinger +5 more
2019Journal of Clinical Medicine19 citations Open access
Semantic Scholar
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
H. Ludwig, W. Pönisch, S. Knop, A. Egle +19 more
2019Leukemia and Lymphoma18 citations Open access
Semantic Scholar
Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer.
C. Hufnagl, M. Leisch, L. Weiss, T. Melchardt +8 more
2019Oncology Letters16 citations Open access
Semantic Scholar
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results
H. Gisslinger, V. Buxhofer-Ausch, J. Thaler, E. Forjan +16 more
2018Blood16 citations
Semantic Scholar
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine—A Prospective Cohort Study by the AGMT
L. Pleyer, S. Heibl, C. Tinchon, S. Vallet +17 more
2023Cancers14 citations Open access
Semantic Scholar
Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence
T. Magnes, S. Wagner, A. Thorner, D. Neureiter +10 more
2021ESMO Open14 citations Open access
Semantic Scholar
Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters
K. Schlick, T. Magnes, Lukas Ratzinger, Bernhard Jaud +4 more
2018PLoS ONE14 citations Open access
Semantic Scholar
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
A. Egle, M. Steurer, T. Melchardt, L. Weiss +12 more
2018Annals of Hematology14 citations Open access
Semantic Scholar
Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy
S. Hatzl, F. Posch, Arwin Rezai, Max Gornicec +13 more
2021Supportive Care in Cancer13 citations Open access
Semantic Scholar
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas
S. Wagner, T. Melchardt, A. Egle, T. Magnes +9 more
2019European Journal of Haematology13 citations Open access
Semantic Scholar
Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol
F. Huemer, S. Hecht, Bernhard Scharinger, V. Schlintl +13 more
2022Journal of Cancer Research and Clinical Oncology12 citations Open access
Semantic Scholar
Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer.
K. Schlick, Steiner Markus, F. Huemer, Lukas Ratzinger +12 more
2021Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]12 citations Open access
Semantic Scholar
Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
S. Wagner, T. Melchardt, R. Greil
2020Drugs of Today12 citations
Semantic Scholar
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)
G. Rinnerthaler, S. Gampenrieder, A. Petzer, S. Burgstaller +12 more
2018BMC Cancer12 citations Open access
Semantic Scholar
Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria
A. Ruckdeschel, Koemm Sabrina, M. Topp, R. Greil +32 more
2023Blood11 citations Open access
Semantic Scholar
Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort
V. Schlintl, F. Huemer, G. Rinnerthaler, T. Melchardt +11 more
2022BMC Cancer10 citations Open access
Semantic Scholar
Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma
B. Chapuy, R. Wurm-Kuczera, R. Michael, Meng Wang +45 more
2025Blood9 citations
Semantic Scholar
880P Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: Primary analysis from the pace ace trial
T. Fuereder, K. Klinghammer, D. Hahn, B. Grünberger +8 more
2024Annals of Oncology9 citations
Semantic Scholar
Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies
T. Magnes, S. Wagner, A. Thorner, D. Neureiter +10 more
2021Cancers9 citations Open access
Semantic Scholar
Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial
G. Rinnerthaler, S. Gampenrieder, H. Hackl, M. Steiner +9 more
2020Journal of Clinical Medicine9 citations Open access
Semantic Scholar
Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
S. Wagner, T. Magnes, T. Melchardt, Dominik Kiem +9 more
2023Anticancer Research8 citations Open access
Semantic Scholar
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group
M. Leisch, M. Pfeilstöcker, R. Stauder, S. Heibl +19 more
2022Cancers8 citations Open access
Semantic Scholar
A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)—AGMT_CML 1
S. Heibl, V. Buxhofer-Ausch, S. Schmidt, G. Webersinke +7 more
2020Hematological Oncology8 citations
Semantic Scholar
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial
A. Egle, T. Melchardt, P. Obrtlíková, L. Smolej +33 more
2019Cancer Medicine7 citations Open access
Semantic Scholar
Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials
Dominik Kiem, Matthias Ocker, Richard Greil, Daniel Neureiter +1 more
2024Expert Opinion on Investigational Drugs6 citations
Semantic Scholar
The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms
Dominik Kiem, S. Wagner, T. Magnes, A. Egle +2 more
2021International Journal of Molecular Sciences6 citations Open access
Semantic Scholar
Multiple myeloma of the mandibular condyle: a rare presentation.
G. Bottini, C. Steiner, T. Melchardt, A. Gaggl
2017British Journal of Oral and Maxillofacial Surgery6 citations
Semantic Scholar
Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
Evgenii Shumilov, R. Wurm-Kuczera, V. Vučinić, Maximilian Seib +32 more
2024Blood5 citations Open access
Semantic Scholar
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
G. Rinnerthaler, S. Gampenrieder, A. Petzer, M. Hubálek +9 more
2021Therapeutic Advances in Medical Oncology5 citations Open access
Semantic Scholar
Ruxolitinib therapy for myelofibrosis in Austria
M. Krauth, S. Burgstaller, V. Buxhofer-Ausch, G. Gastl +10 more
2018Wiener Klinische Wochenschrift5 citations Open access
Semantic Scholar
Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe
E. Aydilek, G. Wulf, F. Schwarz, Ulrike Bacher +8 more
2024Cancer Medicine4 citations Open access
Semantic Scholar
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine—A prospective cohort study by the AGMT
L. Pleyer, Marc Vaisband, Manuel Drost, M. Pfeilstöcker +21 more
2023American journal of hematology/oncology4 citations Open access
Semantic Scholar
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone
T. Magnes, S. Wagner, T. Melchardt, L. Weiss +10 more
2021Wiener Klinische Wochenschrift4 citations Open access
Semantic Scholar
Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients
K. Schlick, Florian Hohla, F. Hamacher, H. Hackl +9 more
2020Future Science OA4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Greil×36
Invite
R. Greil — researcher profile on SciRah
A. Egle×24
Invite
A. Egle — researcher profile on SciRah
T. Magnes×16
Invite
T. Magnes — researcher profile on SciRah
L. Weiss×15
Invite
L. Weiss — researcher profile on SciRah

G. Rinnerthaler

×14

Invite

G. Rinnerthaler — researcher profile on SciRah

Invite

F. Huemer — researcher profile on SciRah

Invite

L. Pleyer — researcher profile on SciRah

Invite

A. Petzer — researcher profile on SciRah

Invite

S. Wagner — researcher profile on SciRah

Invite

N. Zaborsky — researcher profile on SciRah

D. Neureiter×7

Invite

D. Neureiter — researcher profile on SciRah

Invite

M. Leisch — researcher profile on SciRah